Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 2-6 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-2 recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.
COA:
Application Notes:
ELISA or ELISPOT Capture2,3: The purified MQ1-17H12 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated Poly5176 antibody (Cat. No. 517601) as the detecting antibody. The LEAF™ purified antibody is suggested for ELISPOT capture. Neutralization2,3: The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm sterile-filtered) is recommended for neutralization of human IL-2 bioactivity (Cat. No. 500313). The MQ1-17H12 antibody can neutralize the bioactivity of natural or recombinant IL-2. Additional reported applications (for the relevant formats) include: immunoprecipitation2, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections1,4-6,8, and immunocytochemistry. Note: For testing human IL-2 in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 431801 to 431806) are specially developed and recommended.
Application References:
1. Andersson J, et al. 1994. Immunology 83:16. (IHC) 2. Abrams J, et al. 1992. Immunol. Rev. 127:5. (IP) 3. Abrams JS. 1995. Curr. Prot. Immunol. Unit 6.20. 4. Fernandez V, et al. 1994. Eur. J. Immunol. 24:1808. (IHC) 5. Skansen-Saphir U, et al. 1994. Eur. J. Immunol. 24:916. (IHC) 6. Andersson U, et al.Detection and Quantification of Gene Expression. New York:Springer-Verlag. (IHC) 7. Prussin C, et al. 1995. J. Immunol. Methods. 188:117. 8. Raqib R, et al. 2002. Infect. Immun. 70:3199. (IHC) 9. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. PubMed 10. Colleton BA, et al. 2009. J Virol. 83:6288. PubMed 11. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC) 12. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
IL-2 is a potent lymphoid cell growth factor which exerts its biological activity primarily on T cells, promoting proliferation and maturation. Additionally, IL-2 has been found to stimulate growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendrocytes.
Other Names:
Interleukin-2, T cell growth factor (TCGF), Eosinophil differentiation factor (EDF), Killer cell helper factor (KHF), Macrophage-activating factor for cytotoxicity I (MAF-C I), Thymocyte differentiation factor (TDF)
Structure:
Cytokine; 15.4 kD (Mammalian)
Regulation:
Upregulated by NFAT; downregulated by TCF-8 and CIF (colostrums inhibitory factor)
Cellular Sources:
T cells
Cellular Targets:
T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes
Receptors:
High affinity heterotrimer of IL-2Rα/β/γ, intermediate affinity homodimer IL-2Rα (CD25; p55; Tac) and heterodimer IL-2Rβ (CD122)/γ; γ-subunit (CD132) in common with IL-4R, IL-7R, IL-13R, IL-15R
Bioactivity/Activities:
Proliferation of T lymphocytes, B cells, anti-inflammatory, hematopoiesis, tumor surveillance
Antigen References:
1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. Taniguchi T, et al. 1993. Cell 73:5. 3. Nistico G. 1993. Prog. Neurobiol. 40:463. 4. Waldmann T, et al. 1993. Ann. NY Acad. Sci. 685:603.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.
APC anti-human IL-2
PMA + ionomycin-stimulated (6 hours) human peripheral blood lymphocytes intracellular stained with MQ1-17H12 APC and CD3 (UCHT1) PE
FITC anti-human IL-2
5 hours PMA + ionomycin-stimulated human peripheral blood lymphocytes (in the presence of monensin) were stained with CD3 APC, fixed, permeabilized, and then stained with IL-2 (clone MQ1-17H12) FITC (top) or rat IgG2a, κ FITC isotype control (bottom).
LEAF™ Purified anti-human IL-2
PE anti-human IL-2
PMA/Ionomycin-stimulated human PBMCs were stained with CD3 PE/Cy5 and MQ1-17H12 PE
Purified anti-human IL-2
Alexa Fluor® 488 anti-human IL-2
PMA+ionomycin-stimulated (6 hours) human peripheral blood lymphocytes intracellular stained with MQ1-17H12 Alexa Fluor®
488 and CD3 (UCHT1) PE/Cy5
Alexa Fluor® 647 anti-human IL-2
PMA+ionomycin-stimulated (5 hours) human PBMCs surface stained with CD3 PE and intracellular stained with MQ1-17H12 Alexa Fluor® 647
Alexa Fluor® 700 anti-human IL-2
PMA+ionomycin-stimulated (5 hours) human PBMCs surface stained with CD3 PE and intracellular stained with MQ1-17H12 Alexa Fluor® 700
PerCP/Cy5.5 anti-human IL-2
PMA + ionomycin-stimulated (6 hours) human peripheral blood lymphocytes intracellular stained with MQ1-17H12 PerCP/Cy5.5 and CD3 (UCHT1) PE
Pacific Blue™ anti-human IL-2
PMA+ionomycin-stimulated (5 hours) human PBMCs surface stained with CD3 FITC and intracellular stained with MQ1-17H12 Pacific Blue™
PMA+ionomycin-stimulated (5 hours) human PBMCs surface stained with CD3 FITC and intracellular stained with rat IgG2a Pacific Blue™ isotype control
PE/Cy7 anti-human IL-2
PMA+ionomycin-stimulated (6 hours) peripheral blood lymphocytes surface stained with CD3 FITC, then intracellularly stained with MQ1-17H12 PE/Cy7 (top) or rat IgG2a, k PE/Cy7 isotype control (bottom)
Brilliant Violet 421™ anti-human IL-2
Human peripheral blood lymphocytes were stimulated with PMA + Ionomycin for 6 hours (in the presence of monensin), surface stained with CD3 FITC, fixed, permeabilized, and then stained with IL-2 (clone MQ1-17H12) Brilliant Violet 421™ (top) or rat IgG2a, κ Brilliant Violet 421™ isotype control (bottom).
Brilliant Violet 605™ anti-human IL-2
Human peripheral blood lymphocytes were stimulated with PMA + Ionomycin for 6 hours (in the presence of monensin), surface stained with CD3 FITC, fixed, permeabilized, and then stained with IL-2 (clone MQ1-17H12) Brilliant Violet 605™.
Brilliant Violet 650™ anti-human IL-2
PMA+ionomycin-stimulated human peripheral blood lymphocytes were fixed, permeabilized and then stained with IL-2 (clone MQ1-17H12) Brilliant Violet 650™ (top) or rat IgG2a Brilliant Violet 650™ isotype control and CD3 FITC.
